Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down – Time to Sell?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $30.08, but opened at $29.09. Teva Pharmaceutical Industries shares last traded at $29.5250, with a volume of 858,774 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TEVA shares. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Scotiabank raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Stock Performance

The firm has a market cap of $34.04 billion, a price-to-earnings ratio of 24.68, a price-to-earnings-growth ratio of 10.13 and a beta of 0.76. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The firm’s 50 day moving average is $32.15 and its 200-day moving average is $27.85.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the company earned $0.71 earnings per share. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Sabag sold 62,102 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the sale, the insider directly owned 224,940 shares in the company, valued at $6,779,691.60. This trade represents a 21.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric A. Hughes sold 9,533 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the sale, the insider owned 107,711 shares in the company, valued at $3,411,207.37. This trade represents a 8.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 920,901 shares of company stock valued at $30,056,789 in the last 90 days. 0.49% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Phoenix Financial Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after purchasing an additional 3,533,800 shares during the period. National Pension Service increased its holdings in Teva Pharmaceutical Industries by 24.2% in the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Teva Pharmaceutical Industries by 11.5% during the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after purchasing an additional 69,000 shares during the period. Oak Harvest Investment Services bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.